23.55
-2.44%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hybio Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300199.SZ. It has been listed since 7 April 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥966.4m and net income of CN¥36.6m. At that date it held total assets of CN¥3.15bn and shareholders' equity of CN¥614.0m.
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of polypeptide drugs. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2011-04-07. The Company’s products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company's newly added products are pharmaceutical packaging products, medical devices and solid products. The firm is also engaged in provision of related technological services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Apr 2011
- Employees
- 975
- Website
- hybio.com.cn ↗
Leadership
Pay as last reported
- Mr. Shaogui ZengChairman of the Board, President, since 2009CN¥1.0m
- Ms. Pinxiang YuExecutive President, DirectorCN¥1.4m
- Mr. Shaoqiang ZengVice Chairman of the Board, since 2009CN¥60,100
- Mr. Honghong TuChief Financial Officer, Vice PresidentCN¥647,800
- Ms. Di YangVice President, Secretary of the Board, Director, since 2020CN¥1.0m
- Mr. Yangming TangVice President, Director, since 2021CN¥1.1m
- Ms. Min ZhangVice PresidentCN¥708,800
- Mr. Shaobin ZengDirectorCN¥77,700
- Mr. Wenyan HuIndependent DirectorCN¥120,000
- Ms. Zhihong KangIndependent DirectorCN¥120,000
- Mr. Liyong XuIndependent DirectorCN¥4,100
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hybio Pharmaceutical Co Ltd employs 975 full-time employees in Shenzhen, China.
- Hybio's polypeptide drug portfolio includes thymopentin for injection and somatostatin for injection.
- Hybio's subsidiaries offer pharmaceutical packaging products and medical devices as new additions.
Weaknesses
- Hybio's polypeptide API products are limited to specific injection types only.
- Hybio's business relies on a narrow range of polypeptide drug applications.
- Hybio's technological services are not detailed in the provided business description.
Opportunities
- Hybio can expand its polypeptide preparation products to include new injection types.
- Hybio's subsidiaries' pharmaceutical packaging products present a growth opportunity.
- Hybio's medical devices segment could be leveraged for further market expansion.
Threats
- Hybio faces competition from other pharmaceutical companies in the polypeptide drug market.
- Hybio's reliance on injection-based polypeptide drugs may limit market reach.
- Hybio's business is constrained by the narrow scope of its current product offerings.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.